Mass spectrometry (MS)-based proteomics is now used routinely in the National Amyloidosis Centre both as a clinical diagnostic service for amyloidosis and also for research into the pathogenesis of the disease. It is a joint venture between the UCL Wolfson Drug Discovery Unit and the NHS National Amyloidosis Centre.
Proteomics is now considered as the new gold standard for amyloid typing (1,2), providing a direct chemical description of the protein content in the amyloid deposits.
The UK AMYLOID PROTEOMICS (UKAMPRO) facility is the only UKAS-accredited clinical proteomics facility in the UK, and the 2nd largest amyloid proteomics facility in the world.
The laboratory receives tissues for analysis from the UK and overseas as well as from our clinics.
Dr Diana Canetti (Head of Proteomics)
Dr Nigel Rendell (MS Facility Manager)
Dr Graham Taylor (Proteomics Adviser)